Gollnick H P, Finzi A F, Marks R, Barker J N, Jansen C, Revuz J, Saurat J
Klinik für Dermatologie und Venerologie, Otto-von-Guericke-Universität, Magdeburg, Germany.
Dermatology. 1999;199(1):40-6. doi: 10.1159/000018176.
This paper reports the proceedings of the European Advisory Panel Meeting for tazarotene (Zoractrade mark), which took place in Cologne on May 7, 1998.
The aim of this meeting was to discuss recommendations for the use of tazarotene based on the clinical data available and on the clinical experience of the Advisory Panel members, and to identify future research needs.
Based on currently available data, tazarotene can be used for the treatment of chronic, stable, plaque-type psoriasis, on the trunk or limbs covering up to 20% of the body surface area. In clinical trials, patients generally experienced a clinical response within 4 weeks of starting tazarotene treatment, and improvement was maintained for up to 12 weeks after stopping therapy. Results from published and not yet published clinical trials show that the efficacy and tolerability of tazarotene can be enhanced by the addition of topical corticosteroids to the treatment regimen and that, when used in combination with broad-band UVB phototherapy, tazarotene reduces the amount of UV light required to treat plaques. Tazarotene gel is available in two concentrations, 0.05 and 0.1%. The Advisory Panel recommends that the choice of concentration should be based on factors such as the irritability of the patient's skin and the thickness of plaques. Irritation can be managed by reducing the concentration or frequency of application, or by adding a topical corticosteroid to therapy. Tazarotene shows promise as a treatment for psoriasis in special localisations, such as the scalp, face and skin folds, although clinical studies are required.
本文报道了1998年5月7日在科隆举行的他扎罗汀（商品名：索乐）欧洲咨询小组会议的议程。
本次会议的目的是根据现有临床数据和咨询小组成员的临床经验，讨论他扎罗汀的使用建议，并确定未来的研究需求。
根据目前可得的数据，他扎罗汀可用于治疗躯干或四肢慢性、稳定、斑块型银屑病，累及体表面积达20%。在临床试验中，患者在开始他扎罗汀治疗后的4周内通常会出现临床反应，且在停止治疗后改善情况可持续长达12周。已发表和未发表的临床试验结果表明，在治疗方案中添加外用皮质类固醇可提高他扎罗汀的疗效和耐受性，并且当与宽带UVB光疗联合使用时，他扎罗汀可减少治疗斑块所需的紫外线量。他扎罗汀凝胶有0.05%和0.1%两种浓度。咨询小组建议浓度的选择应基于患者皮肤的敏感性和斑块厚度等因素。可通过降低浓度或应用频率，或在治疗中添加外用皮质类固醇来处理刺激反应。尽管需要进行临床研究，但他扎罗汀在治疗特殊部位如头皮、面部和皮肤褶皱处的银屑病方面显示出前景。
